Published in Nephrol Dial Transplant on August 01, 2000
Ascorbic acid or L-arginine improves cutaneous microvascular function in chronic kidney disease. J Appl Physiol (1985) (2011) 1.13
Endothelial function predicts positive arterial-venous fistula remodeling in subjects with stage IV and V chronic kidney disease. J Vasc Access (2011) 0.94
Doppler assessment of brachial artery flow as a measure of endothelial dysfunction in pediatric chronic renal failure. Pediatr Nephrol (2008) 0.89
NADPH oxidase-derived reactive oxygen species contribute to impaired cutaneous microvascular function in chronic kidney disease. Am J Physiol Renal Physiol (2014) 0.83
Effect of medial calcification on vascular function in uremia. Am J Physiol Renal Physiol (2011) 0.82
Dynamics of circulating microparticles in chronic kidney disease and transplantation: Is it really reliable marker? World J Transplant (2015) 0.77
Role of vascular function in predicting arteriovenous fistula outcomes: an observational pilot study. Can J Kidney Health Dis (2015) 0.76
Exploring the Relationships between Hemoglobin, the Endothelium and Vascular Health in Patients with Chronic Kidney Disease. Nephron Extra (2011) 0.76
Abnormalities associated with progressive aortic vascular dysfunction in chronic kidney disease. Front Physiol (2015) 0.75
Defining uremic arterial functional abnormalities in patients recently started on haemodialysis: combined in vivo and ex vivo assessment. PLoS One (2014) 0.75
Pre-treatment considerations in childhood hypertension due to chronic kidney disease. World J Nephrol (2015) 0.75
Open access echocardiography in management of heart failure in the community. BMJ (1995) 7.83
Biochemical detection of left-ventricular systolic dysfunction. Lancet (1998) 7.51
Randomised controlled trial of specialist nurse intervention in heart failure. BMJ (2001) 4.43
Diagnosis and management of heart failure. BMJ (1994) 4.42
Polymorphisms in angiotensin-converting-enzyme gene and progression of IgA nephropathy. Lancet (1995) 4.34
More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail (2001) 4.29
Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995. Circulation (2000) 4.16
Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994. Heart (1999) 4.04
Effect of renal-artery stenting on progression of renovascular renal failure. Lancet (1997) 3.89
Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet (1997) 3.70
Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction. BMJ (1996) 3.59
The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant (2010) 3.35
Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant (2007) 3.02
Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. Kidney Int (2006) 2.80
Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart (2001) 2.78
Trends in hospitalization for heart failure in Scotland, 1990-1996. An epidemic that has reached its peak? Eur Heart J (2001) 2.73
Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients. Am J Transplant (2010) 2.66
Trends in case-fatality in 117 718 patients admitted with acute myocardial infarction in Scotland. Eur Heart J (2000) 2.50
Gender and survival: a population-based study of 201,114 men and women following a first acute myocardial infarction. J Am Coll Cardiol (2001) 2.17
Nurse led, multidisciplinary intervention in chronic heart failure. Heart (1998) 2.05
Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant (2005) 2.01
Age, sex, and social trends in out-of-hospital cardiac deaths in Scotland 1986-95: a retrospective cohort study. Lancet (2001) 1.96
Economics of chronic heart failure. Eur J Heart Fail (2001) 1.80
Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart (2001) 1.77
Prognostic value of cardiovascular screening in potential renal transplant recipients: a single-center prospective observational study. Am J Transplant (2008) 1.73
Helicobacter pylori infection and coronary heart disease in the North Glasgow MONICA population. Eur Heart J (1997) 1.60
Investigation into the sources of superoxide in human blood vessels: angiotensin II increases superoxide production in human internal mammary arteries. Circulation (2000) 1.54
Echocardiography overestimates left ventricular mass in hemodialysis patients relative to magnetic resonance imaging. Kidney Int (1999) 1.50
ACE inhibitors and heart failure in hospital: any difference between cardiologists and general physicians? Postgrad Med J (1999) 1.49
Endothelin B receptors are functionally important in mediating vasoconstriction in the systemic circulation in patients with left ventricular systolic dysfunction. J Am Coll Cardiol (1999) 1.47
Assessing diagnosis in heart failure: which features are any use? QJM (1997) 1.45
Renal replacement treatment in patients with spina bifida or spinal cord injury. BMJ (1989) 1.38
Cost-benefit analysis of lipid lowering therapy. Eur Heart J (1996) 1.38
ABC of arterial and venous disease. Renal artery stenosis. BMJ (2000) 1.36
Cohort study of plasma natriuretic peptides for identifying left ventricular systolic dysfunction in primary care. BMJ (1998) 1.32
Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis. J Pathol (2008) 1.26
Trends in hospital activity, morbidity and case fatality related to atrial fibrillation in Scotland, 1986--1996. Eur Heart J (2001) 1.15
Optimum conditions for cryoquenching of small tissue blocks in liquid coolants. J Microsc (1982) 1.12
Importance of heart failure as a cause of death. Changing contribution to overall mortality and coronary heart disease mortality in Scotland 1979-1992. Eur Heart J (1998) 1.10
Outcome from a rapid-assessment chest pain clinic. QJM (1998) 1.10
QT dispersion before and after hemodialysis. J Am Soc Nephrol (1999) 1.10
Economic aspects of treatment with captopril after MI. Eur Heart J (1996) 1.09
Influence of diabetes mellitus on patient and graft survival in recipients of kidney transplantation. Clin Transplant (2001) 1.08
Continuous ambulatory peritoneal dialysis after the honeymoon: review of experience in Newcastle 1979-84. Br Med J (Clin Res Ed) (1986) 1.08
Serious adverse events experienced by patients with chronic heart failure taking spironolactone. Heart (2001) 1.07
Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study. Am J Transplant (2006) 1.07
The Lys198Asn polymorphism in the endothelin-1 gene is associated with blood pressure in overweight people. Hypertension (1999) 1.06
Effects of UK 69 578: a novel atriopeptidase inhibitor. Lancet (1989) 1.03
Loss of pulsatile luteinising hormone secretion in men with chronic renal failure. Br Med J (Clin Res Ed) (1985) 1.02
Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant (2009) 1.02
Endothelium-derived hyperpolarizing factor : identification and mechanisms of action in human subcutaneous resistance arteries. Circulation (2001) 1.02
Early graft function and patient survival following cadaveric renal transplantation. Kidney Int (1999) 1.02
The prevalence of left ventricular diastolic filling abnormalities in patients with suspected heart failure. Eur Heart J (1997) 1.01
Impaired endothelial function in isolated human uremic resistance arteries. Kidney Int (2001) 0.99
Influence of elevated plasma levels of atrial natriuretic factor on bronchial reactivity in asthma. Am Rev Respir Dis (1991) 0.99
Endothelial dysfunction in renal transplant recipients maintained on cyclosporine. Kidney Int (2000) 0.99
Failure of women's hearts. Circulation (1999) 0.98
Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney Int (2001) 0.96
Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation (1996) 0.95
Colour Doppler ultrasound in renal transplant artery stenosis: which Doppler index? Clin Radiol (1995) 0.95
Failing ageing hearts. Eur Heart J (2001) 0.94
Short-term haemodynamic effects of BQ-123, a selective endothelin ET(A)-receptor antagonist, in chronic heart failure. Lancet (1998) 0.93
Pre-operative echocardiographic abnormalities and adverse outcome following renal transplantation. Nephrol Dial Transplant (1998) 0.90
Electrical cardioversion for atrial fibrillation: outcomes in "real-life" clinical practice. Int J Cardiol (2001) 0.90
Hypertension, antihypertensive agents and outcomes following renal transplantation. Clin Transplant (2005) 0.89
Brain natriuretic peptide is stable in whole blood and can be measured using a simple rapid assay: implications for clinical practice. Heart (1997) 0.89
A closer look at the Autism Behavior Checklist: discriminant validity and factor structure. J Autism Dev Disord (1991) 0.89
Endothelin in chronic heart failure: current position and future prospects. Cardiovasc Res (1996) 0.89
Spontaneous subconjunctival haemorrhage--a sign of hypertension? Br J Ophthalmol (1992) 0.89
QT dispersion in patients with chronic heart failure: beta blockers are associated with a reduction in QT dispersion. Heart (1999) 0.88
Endothelin receptor antagonism in patients with chronic heart failure. Cardiovasc Res (2000) 0.87
Inappropriately low plasma leptin concentration in the cachexia associated with chronic heart failure. Heart (1999) 0.87
Circulating endothelin in acute ischaemic syndromes. Br Heart J (1992) 0.87
Vascular function in patients with end-stage renal disease and/or coronary artery disease: a cardiac magnetic resonance imaging study. Kidney Int (2006) 0.87
Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. J Am Coll Cardiol (2001) 0.87
Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation. Am J Transplant (2005) 0.87
Pulmonary extraction and left atrial secretion of atrial natriuretic factor during cardiopulmonary bypass surgery. Am Heart J (1992) 0.86
Dolly, no longer the exception: telomeres and implications for transplantation. Cloning Stem Cells (2003) 0.85
Effect of atrial natriuretic factor on bronchomotor tone in the normal human airway. Clin Sci (Lond) (1990) 0.85
DR antigens and Bf allotypes in north-east England. Hum Hered (1985) 0.85
The impact of late acute rejection after cadaveric kidney transplantation. Clin Transplant (2001) 0.85
The role of genetic polymorphisms of angiotensin-converting enzyme in the progression of renal diseases. Hypertension (1996) 0.84
Role of bradykinin in the vasodilator effects of losartan and enalapril in patients with heart failure. Circulation (1999) 0.84
Early echocardiographic changes and survival following renal transplantation. Nephrol Dial Transplant (2000) 0.84
Heart failure: the Cinderella of cardiology? Public Health (1997) 0.84
Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure. Eur J Heart Fail (1999) 0.84
The effect of renal impairment on the pharmacokinetics and metabolism of bopindolol. Br J Clin Pharmacol (1991) 0.83
Value of ECGs in identifying heart failure due to left ventricular systolic dysfunction. BMJ (1996) 0.83
Renal function and cardiovascular events: relevance of eGFR and albuminuria in patients with diabetes. Diabetologia (2010) 0.83
Renin angiotensin system inhibition is associated with reduced free radical concentrations in arteries of patients with coronary heart disease. Heart (2001) 0.83